MediPal Holdings Corporation
MediPal Holdings Corporation MEPDF Peers
See (MEPDF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MEPDF | $17.57 | N/A | 3.65B | 13.21 | $1.33 | +2.41% |
| SHPMF | $1.56 | +0.13% | 9.19B | 9.76 | $0.16 | +4.33% |
| SHTDY | $11.75 | +1.08% | 7.41B | 7.48 | $1.57 | +5.11% |
| SHTDF | $2.35 | N/A | 7.33B | 7.58 | $0.31 | +5.21% |
| CAKFY | $4.10 | N/A | 5.37B | -68.33 | -$0.06 | N/A |
| AMFPF | $22.02 | N/A | 4.95B | 31.01 | $0.71 | +1.48% |
| GALNF | $75.25 | N/A | 3.75B | 20.23 | $3.72 | +3.69% |
| MAHLY | $15.68 | N/A | 3.26B | 11.79 | $1.33 | +1.76% |
| ALFRY | $15.99 | +19.15% | 2.91B | 15.38 | $1.04 | N/A |
| ARHCF | $11.87 | N/A | 2.27B | 9.97 | $1.19 | +0.03% |
Stock Comparison
MEPDF vs SHPMF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, SHPMF has a market cap of 9.19B. Regarding current trading prices, MEPDF is priced at $17.57, while SHPMF trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas SHPMF's P/E ratio is 9.76. In terms of profitability, MEPDF's ROE is +0.08%, compared to SHPMF's ROE of +0.06%. Regarding short-term risk, MEPDF is more volatile compared to SHPMF. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs SHTDY Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, SHTDY has a market cap of 7.41B. Regarding current trading prices, MEPDF is priced at $17.57, while SHTDY trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas SHTDY's P/E ratio is 7.48. In terms of profitability, MEPDF's ROE is +0.08%, compared to SHTDY's ROE of +0.09%. Regarding short-term risk, MEPDF is more volatile compared to SHTDY. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs SHTDF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, SHTDF has a market cap of 7.33B. Regarding current trading prices, MEPDF is priced at $17.57, while SHTDF trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas SHTDF's P/E ratio is 7.58. In terms of profitability, MEPDF's ROE is +0.08%, compared to SHTDF's ROE of +0.06%. Regarding short-term risk, MEPDF is more volatile compared to SHTDF. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs CAKFY Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, CAKFY has a market cap of 5.37B. Regarding current trading prices, MEPDF is priced at $17.57, while CAKFY trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas CAKFY's P/E ratio is -68.33. In terms of profitability, MEPDF's ROE is +0.08%, compared to CAKFY's ROE of -0.02%. Regarding short-term risk, MEPDF is more volatile compared to CAKFY. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs AMFPF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, AMFPF has a market cap of 4.95B. Regarding current trading prices, MEPDF is priced at $17.57, while AMFPF trades at $22.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas AMFPF's P/E ratio is 31.01. In terms of profitability, MEPDF's ROE is +0.08%, compared to AMFPF's ROE of +0.13%. Regarding short-term risk, MEPDF is more volatile compared to AMFPF. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs GALNF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, GALNF has a market cap of 3.75B. Regarding current trading prices, MEPDF is priced at $17.57, while GALNF trades at $75.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas GALNF's P/E ratio is 20.23. In terms of profitability, MEPDF's ROE is +0.08%, compared to GALNF's ROE of +0.12%. Regarding short-term risk, MEPDF is more volatile compared to GALNF. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs MAHLY Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, MAHLY has a market cap of 3.26B. Regarding current trading prices, MEPDF is priced at $17.57, while MAHLY trades at $15.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas MAHLY's P/E ratio is 11.79. In terms of profitability, MEPDF's ROE is +0.08%, compared to MAHLY's ROE of +0.06%. Regarding short-term risk, MEPDF is less volatile compared to MAHLY. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs ALFRY Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, ALFRY has a market cap of 2.91B. Regarding current trading prices, MEPDF is priced at $17.57, while ALFRY trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas ALFRY's P/E ratio is 15.38. In terms of profitability, MEPDF's ROE is +0.08%, compared to ALFRY's ROE of +0.05%. Regarding short-term risk, MEPDF is more volatile compared to ALFRY. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs ARHCF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, ARHCF has a market cap of 2.27B. Regarding current trading prices, MEPDF is priced at $17.57, while ARHCF trades at $11.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas ARHCF's P/E ratio is 9.97. In terms of profitability, MEPDF's ROE is +0.08%, compared to ARHCF's ROE of +0.05%. Regarding short-term risk, MEPDF is more volatile compared to ARHCF. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs SZUKF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, SZUKF has a market cap of 1.72B. Regarding current trading prices, MEPDF is priced at $17.57, while SZUKF trades at $30.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas SZUKF's P/E ratio is 11.43. In terms of profitability, MEPDF's ROE is +0.08%, compared to SZUKF's ROE of +0.04%. Regarding short-term risk, MEPDF is more volatile compared to SZUKF. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs SHPMY Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, SHPMY has a market cap of 1.70B. Regarding current trading prices, MEPDF is priced at $17.57, while SHPMY trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas SHPMY's P/E ratio is 8.43. In terms of profitability, MEPDF's ROE is +0.08%, compared to SHPMY's ROE of +0.06%. Regarding short-term risk, MEPDF is more volatile compared to SHPMY. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs IUSDF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, IUSDF has a market cap of 1.66B. Regarding current trading prices, MEPDF is priced at $17.57, while IUSDF trades at $23.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas IUSDF's P/E ratio is 30.05. In terms of profitability, MEPDF's ROE is +0.08%, compared to IUSDF's ROE of +0.12%. Regarding short-term risk, MEPDF is less volatile compared to IUSDF. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs MEDOF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, MEDOF has a market cap of 1.28B. Regarding current trading prices, MEPDF is priced at $17.57, while MEDOF trades at $50.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas MEDOF's P/E ratio is 73.53. In terms of profitability, MEPDF's ROE is +0.08%, compared to MEDOF's ROE of +0.03%. Regarding short-term risk, MEPDF is less volatile compared to MEDOF. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs ARRJF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, ARRJF has a market cap of 836.17M. Regarding current trading prices, MEPDF is priced at $17.57, while ARRJF trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas ARRJF's P/E ratio is 18.06. In terms of profitability, MEPDF's ROE is +0.08%, compared to ARRJF's ROE of +0.06%. Regarding short-term risk, MEPDF is less volatile compared to ARRJF. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs ENMI Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, ENMI has a market cap of 15.33M. Regarding current trading prices, MEPDF is priced at $17.57, while ENMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas ENMI's P/E ratio is -0.40. In terms of profitability, MEPDF's ROE is +0.08%, compared to ENMI's ROE of +0.51%. Regarding short-term risk, MEPDF is more volatile compared to ENMI. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs EXHI Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, EXHI has a market cap of 15.06M. Regarding current trading prices, MEPDF is priced at $17.57, while EXHI trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas EXHI's P/E ratio is N/A. In terms of profitability, MEPDF's ROE is +0.08%, compared to EXHI's ROE of +0.00%. Regarding short-term risk, MEPDF is more volatile compared to EXHI. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs NSVGF Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, NSVGF has a market cap of 8.48M. Regarding current trading prices, MEPDF is priced at $17.57, while NSVGF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas NSVGF's P/E ratio is -1.00. In terms of profitability, MEPDF's ROE is +0.08%, compared to NSVGF's ROE of +0.21%. Regarding short-term risk, MEPDF is more volatile compared to NSVGF. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs PDRX Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, PDRX has a market cap of 4.25M. Regarding current trading prices, MEPDF is priced at $17.57, while PDRX trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas PDRX's P/E ratio is 2.55. In terms of profitability, MEPDF's ROE is +0.08%, compared to PDRX's ROE of -0.07%. Regarding short-term risk, MEPDF is more volatile compared to PDRX. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs KOSK Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, KOSK has a market cap of 3.85M. Regarding current trading prices, MEPDF is priced at $17.57, while KOSK trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas KOSK's P/E ratio is -0.20. In terms of profitability, MEPDF's ROE is +0.08%, compared to KOSK's ROE of -0.13%. Regarding short-term risk, MEPDF is more volatile compared to KOSK. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs ITNS Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, ITNS has a market cap of 609364.00. Regarding current trading prices, MEPDF is priced at $17.57, while ITNS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas ITNS's P/E ratio is -0.04. In terms of profitability, MEPDF's ROE is +0.08%, compared to ITNS's ROE of +0.01%. Regarding short-term risk, MEPDF is more volatile compared to ITNS. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs PHRX Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, PHRX has a market cap of 5171.00. Regarding current trading prices, MEPDF is priced at $17.57, while PHRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas PHRX's P/E ratio is N/A. In terms of profitability, MEPDF's ROE is +0.08%, compared to PHRX's ROE of +0.85%. Regarding short-term risk, MEPDF is less volatile compared to PHRX. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs CHME Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, CHME has a market cap of 2380.00. Regarding current trading prices, MEPDF is priced at $17.57, while CHME trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas CHME's P/E ratio is N/A. In terms of profitability, MEPDF's ROE is +0.08%, compared to CHME's ROE of +0.04%. Regarding short-term risk, MEPDF is more volatile compared to CHME. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs MLTO Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, MLTO has a market cap of 1700.00. Regarding current trading prices, MEPDF is priced at $17.57, while MLTO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas MLTO's P/E ratio is -0.00. In terms of profitability, MEPDF's ROE is +0.08%, compared to MLTO's ROE of N/A. Regarding short-term risk, MEPDF is less volatile compared to MLTO. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.
MEPDF vs TGVN Comparison
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.65B. In comparison, TGVN has a market cap of 120.00. Regarding current trading prices, MEPDF is priced at $17.57, while TGVN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 13.21, whereas TGVN's P/E ratio is -0.00. In terms of profitability, MEPDF's ROE is +0.08%, compared to TGVN's ROE of N/A. Regarding short-term risk, MEPDF is more volatile compared to TGVN. This indicates potentially higher risk in terms of short-term price fluctuations for MEPDF.